article thumbnail

STAT+: Lilly’s Zepbound slashed risk of developing diabetes

STAT

Eli Lilly’s obesity drug Zepbound significantly cut the risk of developing type 2 diabetes, showing the benefits of long-term use of the blockbuster therapy. In that study, which enrolled people with obesity and heart disease, Wegovy also cut the risk of developing diabetes by 73%. The company did not report absolute risk rates.

Diabetes 363
article thumbnail

Screen early in pregnancy for gestational diabetes, new Lancet series urges

STAT

Gestational diabetes affects one in seven expecting women globally and rates of this troubling condition are rising.   Gestational diabetes has long been diagnosed between weeks 24 and 28 of pregnancy.

Diabetes 341
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

In children, Covid is tied to higher risk of type 2 diabetes 

STAT

It may be time to add Covid-19 infection to the list of possible risk factors for developing type 2 diabetes at a young age.  Children with obesity were twice as likely to have new type 2 diabetes post-Covid and those who were sick enough to be hospitalized were almost three times as likely to do so. Read the rest…

Diabetes 363
article thumbnail

STAT+: Vertex reports positive results in stem cell trial for type 1 diabetes

STAT

ORLANDO — Twelve people with type 1 diabetes who received a therapy derived from stem cells were able to produce enough of their own insulin to maintain healthy blood glucose levels 90 days later, Vertex Pharmaceuticals said Friday.

Diabetes 363
article thumbnail

STAT+: Sanders blames food companies for diabetes epidemic

STAT

Sanders held a hearing today on diabetes that implicated both the food and drug industries in what the American Diabetes Association estimates is a $413 billion annual cost to the health care system. WASHINGTON — Sen. Bernie Sanders (I-Vt.) has a new corporate target: the food industry.

Diabetes 351
article thumbnail

STAT+: Ozempic cut risk of death in diabetes patients with chronic kidney disease

STAT

Novo Nordisk’s Ozempic cut the risk of death in a trial of patients with type 2 diabetes and chronic kidney disease, suggesting it may offer some added benefits over other classes of drugs approved to treat this population. Specifically, the diabetes drug cut the risk of cardiovascular-related deaths by 29% and all-cause deaths by 20%.

Diabetes 359
article thumbnail

Ozempic linked to lower opioid overdose rate in those with diabetes, study shows

STAT

People taking semaglutide medications like Ozempic for diabetes may be at reduced risk of drug overdose, according to new research.

Diabetes 353